Contact your healthcare provider if you experience: Severe or expanding redness erythema extending beyond 2-3 inches from the injection site or worsening after 48 hours Signs of infection increasing warmth, purulent drainage, fever, or systemic symptoms suggesting cellulitis or abscess formation Persistent nodules or lumps firm masses that do not resolve within several weeks may indicate lipohypertrophy or sterile abscess Widespread rash or hives urticaria beyond the injection site suggests possible systemic hypersensitivity Angioedema swelling of the face, lips, tongue, or throat, which may indicate a serious allergic reaction requiring emergency care Blistering or skin breakdown vesiculation or ulceration at injection sites is abnormal and requires evaluation Seek immediate emergency care (call 911 or go to the nearest emergency department) for: Difficulty breathing, wheezing, or throat tightness Rapid onset of generalized urticaria or angioedema Dizziness, syncope, or signs of anaphylaxis Severe, persistent abdominal pain (may radiate to the back) with or without vomiting (to exclude pancreatitis) If you suspect a serious hypersensitivity reaction, discontinue tirzepatide immediately and seek urgent medical care
The two together could worsen the side effects as experienced by patients
A 2.5 mg track has short direct data and real-world support for stable maintainers, but continuing tirzepatide has much stronger evidence than stopping. At week 112, stepping down to 5 mg preserved 16.6% weight loss versus 21.9% on the top dose and 9.9% on placebo
Simple strategies like smaller meals, avoiding sulfur-rich foods, and staying hydrated can make a noticeable difference
The target zone: anterior and lateral thigh The ideal injection zone is the front (anterior) and outer (lateral) surface of the thigh
A licensed provider will review your health profile and create a personalized plan
